Paper Details

  1. Home
  2. Paper Details

Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.

Author: FachiMariana M, Fernandez-LlimosFernando, LeonartLeticia P, PontaroloRoberto, RottaInajara, ToninFernanda S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review and network meta-analysis compares the safety profiles of different tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia. The analysis found that all TKIs are associated with haematological toxicities, but there are differences in the frequency and severity of these effects.
Paper Details　
Original Abstract of the Article :
Despite their overall favourable safety profile, tyrosine kinase inhibitors (TKIs) are related to severe adverse events including haematological toxicities such as anaemia, leucopenia, neutropenia and thrombocytopenia. We designed a systematic review and network meta-analysis of randomised controlle...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783623/

データ提供：米国国立医学図書館（NLM）

Navigating the Side Effects of Tyrosine Kinase Inhibitors

Tyrosine kinase inhibitors (TKIs) are powerful drugs used to treat chronic myeloid leukemia, but they can come with side effects, particularly hematological toxicities. This research delves into the safety profile of different TKIs, comparing their effects on blood cell counts. It's like navigating a treacherous desert, where the path can be fraught with unexpected dangers.

Comparing the Safety of Different TKIs

The study, a network meta-analysis of randomized controlled trials, aimed to compare the safety of six TKIs: bosutinib, dasatinib, imatinib, nilotinib, ponatinib, and radotinib. This type of analysis is like creating a map of the desert, highlighting the different risks associated with each path. The research found that while TKIs generally have a favorable safety profile, they can lead to various hematological toxicities, such as anemia, leukopenia, neutropenia, and thrombocytopenia. The study also identified differences in the risk of specific side effects among the different TKIs.

Informed Decision-Making in Cancer Treatment

This research provides valuable information for healthcare providers who are selecting TKIs for their patients with chronic myeloid leukemia. It's like having a trusty guide in the desert, providing insights to help make informed decisions about treatment. By understanding the potential side effects of different TKIs, healthcare providers can tailor treatment plans to minimize risks and improve patient outcomes.

Dr.Camel's Conclusion

This study offers a comprehensive overview of the safety profile of different TKIs used in the treatment of chronic myeloid leukemia. It highlights the importance of balancing the benefits and risks of these drugs, carefully considering individual patient factors to create personalized treatment plans. As we journey through the desert of cancer treatment, it's crucial to have a clear understanding of the potential side effects of medications and make informed decisions that prioritize patient safety and well-being.

Date :
  1. Date Completed 2020-09-23
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

30907446

DOI: Digital Object Identifier

PMC6783623

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.